KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Non-Current Assets: 2018-2025

Historic Non-Current Assets for Esperion Therapeutics (ESPR) over the last 8 years, with Sep 2025 value amounting to $3.6 million.

  • Esperion Therapeutics' Non-Current Assets fell 45.78% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year decrease of 45.78%. This contributed to the annual value of $5.8 million for FY2024, which is 23.08% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Non-Current Assets of $3.6 million as of Q3 2025, which was down 20.80% from $4.5 million recorded in Q2 2025.
  • Esperion Therapeutics' 5-year Non-Current Assets high stood at $54.6 million for Q3 2021, and its period low was $1.2 million during Q1 2023.
  • Its 3-year average for Non-Current Assets is $4.7 million, with a median of $4.7 million in 2023.
  • As far as peak fluctuations go, Esperion Therapeutics' Non-Current Assets spiked by 874.13% in 2022, and later plummeted by 97.67% in 2023.
  • Quarterly analysis of 5 years shows Esperion Therapeutics' Non-Current Assets stood at $52.6 million in 2021, then crashed by 97.61% to $1.3 million in 2022, then soared by 276.67% to $4.7 million in 2023, then climbed by 23.08% to $5.8 million in 2024, then slumped by 45.78% to $3.6 million in 2025.
  • Its last three reported values are $3.6 million in Q3 2025, $4.5 million for Q2 2025, and $5.3 million during Q1 2025.